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Abstract
The concept of activated microglia being associated with neurodegenerative pathological 
structures in aging and Alzheimer’s disease (AD) has been well established, but ques-
tions remain about how well are we defining “what are microglia actually doing” when 
we look at diseased or aged brains? Most studies of microglia in human AD brains have 
employed a limited set of antigenic markers, particularly the major histocompatibility 
complex protein HLA-DR and ionized calcium-binding adaptor molecule IBA-1, along 
with cellular morphological criteria, but in recent years, it has been appreciated that 
microglial responses are very heterogeneous depending on their surrounding environ-
ment—every microglia might be different. Initial observations on human brain microglia 
associated with plaques and tangles suggested that microglial inhibition with broad 
spectrum anti-inflammatory drugs should slow down AD pathology, but clinical trials 
did not show this approach to be effective. In this article, we will consider the needs, chal-
lenges and benefits for refining how microglia are defined as they associate with patho-
logical proteins. This may aid in defining which ones are accelerating neurotoxicity and 
which ones are performing reparative/phagocytic functions. More complete definition 
of microglial phenotypes offers the potential of developing targeted anti-inflammatory 
approaches for this disease.
Keywords: neuroinflammation, pathology, immunohistochemistry, antibodies, 
activation, microglia
1. Introduction
Progress in developing new treatment approaches for Alzheimer’s disease (AD) has been slow. 
The goals of identifying key pathological events early in the disease and preventing them from 
progressing further has been investigated for many approaches; including preventing amyloid 
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formation and/or aggregation [1, 2], preventing tau phosphorylation and aggregation [3], reduc-
ing mitochondrial dysfunction and production of reactive oxygen species with various anti-oxi-
dants [4, 5], enhancing autophagy [6], reducing the consequences of abnormal lipid metabolism 
[7], and targeting inflammation and microglia [8] amongst others with limited effectiveness. 
Since the identification of increased inflammation in AD brains, first characterized more than 
30 years by increased expression by microglia of HLA-DR [9], and subsequently for other mac-
rophage proteins, including beta II integrins and immunoglobulin Fc receptors CD16, CD32 
and CD64 [10, 11], ferritin [12, 13], CD68 [14, 15] amongst others, led to the development of 
the inflammation hypothesis for AD that suggested that inflammatory products were driving 
the loss of synapses and neurons in this disease [16]. If this were true, reducing inflammation 
should have shown great potential for treating AD, however; this approach has not been suc-
cessful to date [17, 18].
The initial studies identified several features about the microglia associated with AD plaque 
and tangle pathology. There was increased expression of the MHC class II marker HLA-DR, 
and morphologically the microglia were different with thicker cell processes and enlarged 
cell bodies [19]. From these initial observations, it was concluded that the microglia were in 
a pro-inflammatory state and thus must be producing neurotoxic cytokines that would be 
accelerating the progression of disease. This hypothesis is illustrated in Figure 1, where in 
this illustration aggregated amyloid beta (Aβ) peptide, produced as an initial feature of AD, 
activates the microglia, which can produce cytokines such as tumor necrosis factor (TNF)-α or 
interleukin (IL)-1β that accelerate neuronal dysfunction. This scheme was supported by exper-
imental studies showing that aggregated/fibrillar Aβ had strong proinflammatory-inducing 
properties on microglia, including activation of the NADPH oxidase complex of myelocytic 
Figure 1. Microglia are performing multiple functions in Alzheimer’s disease brains. How should microglia be classified 
in human brains. Scheme to illustrate the potential change in activation of microglia with development of disease. The 
morphologies of resting or surveilling microglia is established, but it is apparent that activated-cytotoxic-microglia 
in brain tissue may be indistinguishable from the activated-reparative or -phagocytic microglia. The observation of 
ameboid microglia in AD tissue without other pathology (infarcts/hemorrhage) involving lymphocyte infiltration is rare.
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cells that leads to a burst of production of highly toxic reactive oxygen species [20, 21], 
as well as induction of many proinflammatory genes [22]. Another feature of this figure, which 
could be as important, is the other (non-proinflammatory) microglia that will be present in 
the AD pathological environment. There has been insufficient attention to describing these 
microglia, but they will play an essential role in phagocytosis of Aβ as well as performing 
other homeostatic functions. It has been hypothesized that one could distinguish between 
these microglia based mainly on cellular morphology; however there are limited data to sup-
port this. The presence of activated microglia in AD tissues provided the rationale for testing 
of “non-specific” non-steroidal anti-inflammatory drugs (NSAIDS) in AD patients. There had 
been supporting, though not unanimous, data that subjects with a history of long term anti-
inflammatory drug usage also seemed to be protected from dementia [23–25]. Controlled drug 
trials of NSAIDs or related agents in AD patients have never shown significant effectiveness 
in slowing disease progression, and even these widely-used agents appear to have significant 
side effects in elderly subject. It has been argued that these trials failed because the disease 
was too far progressed to respond to therapy, but we will posit in this article that maybe our 
understanding of the unique features of inflammation in AD are still not complete enough 
for selecting appropriate drug treatments. This comes back to the central question of “what 
are the activated microglia actually doing” in the AD brain [17, 18]. Such studies need adequate 
numbers of quality tissue samples from control and AD cases. The presence of AD plaque and 
tangle pathology is also a common feature in aged brains without clinical dementia. These 
cases, called high pathology controls or high plaque non-demented, are particularly valuable 
for neuroinflammation studies as they provide material for studying what might be pre-AD 
stages of microglial activation. Being able to describe progression of inflammatory changes 
leading AD could be critical for identifying therapeutic targets.
2. Dichotomy of microglial function: do we know which microglia 
are producing damaging inflammation and which are performing 
phagocytosis of damaging abnormal proteins
Since the initial discoveries of activated microglia in AD and aging brains, the concepts and 
knowledge of what microglia are doing or could potentially be doing has progressed. The 
central role of microglia in brain, or macrophages in general, is to phagocytose and digest 
cellular waste products, which should include the extra-cellular Aβ that is deposited in AD 
and aging brains. An important question that is still unanswered today is “why are microglia 
not doing a better job of removing Aβ plaques?” Some concepts of microglial function in 
relation to AD came from transgenic mouse models using animals engineered to develop Aβ 
plaques in a manner similar to humans. These studies produced some conflicting results, but 
in general it was shown that microglia could be manipulated to achieve greater removal of 
plaque material, but in these mice, as in humans, microglial removal of plaque material is not 
efficient without some stimuli [26]. Again, we can ask does this apply to all microglia? Certain 
cytokine treatments affect microglia leading to reduced phagocytosis such that plaque mate-
rial accumulates to a greater extent [27–29]. These studies illustrated how microglia can be 
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activated to be more or less efficient at Aβ removal [30, 31]. This was particularly shown in 
Aβ-peptide immunized mice, which had produced a specific antibody response to plaque 
material. The coating of plaques with anti-Aβ immunoglobulin appeared to promote phago-
cytosis through engagement of the microglial IgG Fc receptors. Overall, these studies showed 
that microglia of a particular phenotype have the potential to remove Aβ; similar observa-
tions have come from human pathological studies in certain subjects who had received the 
Aβ vaccine [14].
3. Schemes for defining microglial function: limitations of M1 and 
M2 activation state definitions
Phenotyping of macrophages and microglia progressed with the pioneering work of Gordon 
and colleagues who sought to develop schemes for classification of macrophages, first in 
mice and then in humans, by assigning activation states to the expression of different anti-
genic markers based on responses to defined activation stimuli [32, 33]. Much of this work 
employed gene expression profiling mRNA analysis since these techniques have fewer of the 
limitations associated with antibodies that will be discussed. These phenotyping schemes 
were also applied to microglia, both rodent and human. The scheme defined classical activa-
tion or M1 activation, as being the state of macrophages/microglia that have been stimulated 
with strong inflammatory agents such as lipopolysaccharide (LPS) and interferon gamma 
(IFN-γ). Such activated cells will be expressing increased levels of cytokines and enzymes 
such as TNF-α, IL-1β, IL6, matrix metalloproteinase (MMP)-3 and MMP-9. The corollary to 
this is alternative activation or M2, which defines the markers and products of cells respond-
ing to anti-inflammatory cytokines such as IL-4 or IL-13. These cells have a reparative/neuro-
trophic phenotype and can produce growth factors. Such reparative M2 microglia also show 
increased phagocytosis. The M2 scheme was further subdivided into M2a (responses to IL4 
or IL13), M2b (responses to immune complexes in combination with IL-1β or LPS) and M2c 
(responses to anti-inflammatory IL-10, TGFβ or glucocorticoids). It was shown that increased 
expression of the scavenger receptor CD163, a marker for M2c was upregulated in microglia 
in AD and Parkinson disease dementia cases. This is the first study showing a type of alterna-
tive activation in AD tissues by immunohistochemistry [34].
Many studies have tried to apply these schemes to tissue microglia but their validity has been 
contested [35]. The schemes are dependent on using defined stimuli, while in the degenerat-
ing AD brain, there will be many different stimuli (Aβ and tau in different conformations, 
reactive oxygen, cytokines, bioactive lipids, ATP/ADP, DNA, etc.) that will account for the 
heterogeneity of microglia responses in tissue. In recent years, there has been criticism that 
the M1 and M2 scheme is not applicable for tissue microglia as such defined microglia do not 
seem to exist in brain [35]. This may be correct as the microenvironment around every plaque 
and every neuron will be different, but to attempt to profile microglia does require some form 
of scheme, even an imperfect one, to relate to function. It will also be proposed that the limita-
tions of the M1 and M2 classification schemes could be due to technical reasons as much as 
biological reasons.
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4. Practical issues involved in microglial phenotyping in human 
autopsy brains
Success in classifying microglia in postmortem human autopsy tissue sections is primarily 
dependent on the antibodies being used for this purpose, but also the manner in which the 
brain tissue being studied was preserved. Many published studies of microglial markers for 
immunohistochemistry have been restricted to antibodies that produce strong immunoreac-
tivity on extensively fixed tissue sections. This is particularly true for HLA-DR, which is the 
most widely used for human microglial studies, as available antibodies can produce vivid 
results on a wide range of preserved brain tissue. The following references are the first for 
HLA-DR and the most recent, spanning 30 years of studies [36, 37]. The function of HLA-DR 
in AD microglia is still unclear. This protein functions to present processed antigens to T 
lymphocytes that are not present in the AD microenvironment. The signaling that leads to 
upregulation of HLA-DR in AD microglia has not been defined. In recent years, the marker 
IBA-1, which recognizes an actin-binding protein involved in cytoskeletal reorganization and 
cell motility, has also been extensively used to identify microglia because of the availability of 
robust staining antibodies [38]. IBA-1 antibodies seem to recognize all microglia with limited 
upregulation in activated microglia, though this interpretation is also dependent on observa-
tions related to microglial morphology. The use of antibodies that produce strong results in 
tissue sections may have biased our understanding of microglial function in disease as many 
other antigenic markers are present, but suitable antibodies to reveal them in tissue are not 
available. Most useful markers of function are cell-surface glycosylated proteins whose anti-
genicity become significantly affected by fixation conditions and also by the degree of glyco-
sylation. The most widely available tissues for many researchers are tissue blocks that have 
been formalin-fixed for extended periods and then embedded in paraffin (FFPE); this process 
includes treatments with xylene. These preservation methods strongly affect the ability of 
antibodies to recognize many antigens, but in particular cell-surface glycoproteins. The num-
bers of antibodies that are effective at antigen recognition on FFPE tissue are a small percent-
age of available antibodies. In addition, the use of FFPE tissue usually requires the application 
of antigen retrieval techniques for most antibodies to work; there are a range of these methods 
but their successful application is dependent on operator skill and can lack reproducibility. 
As mentioned, the applicability of M1 and M2-like schemes to classify microglia in human 
brain samples has been criticized as many of the classification antigens have not been proven 
in tissue microglia [35], however such schemes may have been prematurely discarded due to 
the lack of panels of antibodies functional on available brain tissue samples.
4.1. Previous studies of microglial functional proteins in AD
Since the initial studies of increased HLA-DR expression by microglia in AD brains, in areas 
associated with pathology [9, 19, 36, 39–42], expression of a range of macrophage markers have 
been applied to AD brain tissues. These include beta II integrins (CD11a, b, and c and CD18—
complement and phagocytic receptors), immunoglobulin Fc receptors (CD16, CD32, CD64) 
[11], lipopolysaccharide receptor CD14 [43], macrophage colony stimulating factor receptor-1 
(CSF-1R; CD115) [44], type B scavenger receptor CD36 [45, 46], ferritin [47], signal regulatory 
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protein beta-1 (SIRPβ-1) [48] and progranulin [49]. The markers CD43 and TMEM106B were 
shown to be downregulated in AD microglia compared to controls [50, 51]. This represents 
an incomplete list due to space limitations but many of these markers are related to phago-
cytic function rather than cytotoxicity. Ferritin has unique properties in relation to microglial 
activation as it is a ubiquitous iron transport protein but in tissue seems to selectively iden-
tify a population of activated microglia [12, 13]. To directly demonstrate potential cytotoxic-
ity, the demonstration of increased levels of cytokines in microglia is needed. Over the last 
30 years, there have been few studies using immunohistochemistry to profile cytokines in tis-
sue sections. A series of studies by Griffin and colleagues showed IL-1α-expressing microglia 
were associated with different types of plaques and tangles. Diffuse neuritic and non-neuritic 
plaques had the most IL-1α positive microglia, while dense core neuritic and non-neuritic 
plaques had significantly few IL-1α positive microglia. These results suggest that this popula-
tion of microglia were involved at early stages of plaque formation [52]. Use of this marker 
demonstrated that IL-1α positive microglia were involved in the generation of neurofibril-
lary tangles in the parahippocampal gyrus [53]. In another study, it was shown that IL-1β 
and TNF-α could be localized to microglia in human AD tissue [42]. The limited numbers of 
studies do highlight the technical difficulties of detecting secreted proteins such as cytokines. 
Griffin and colleagues employed FFPE tissue for immunohistochemistry. We have attempted 
a number of times using our short-fixed microtome cut sections to localize cytokines to tissue 
and have never been successful. As these molecules are secreted rather than membrane local-
ized, it is possible the hard fixation involved in FFPE is needed to anchor them, and then anti-
gen retrieval to allow antibody access. With short fixed brain tissues materials, these soluble 
proteins might not be adequately fixed in situ for localization.
4.2. Selecting antibodies for microglial phenotyping
The whole field of human brain immunohistochemistry has several limitations when it comes 
to selection of suitable antibodies needed to reveal location of proteins of interest. Firstly, the 
antibody, usually a monoclonal antibody of mouse or rabbit origin, thus specific to an epitope 
representing a small portion of the target protein, has to be able to show specificity—namely 
it is actually recognizing the target protein in situ and not cross reacting with other proteins. 
Secondly, the antibody, if it can be validated to recognize the target protein in tissue, its speci-
ficity and sensitivity can be affected by the fixation conditions. In our experience, the study of 
microglial antigens with a wider range of antibodies has been less problematic using brain tis-
sue fixed for a short period (48 h) in paraformaldehyde (not formalin) and then cryoprotected 
and sectioned using a freezing microtome. This process avoids the harsh treatments involved 
in paraffin embedding of tissue. Over the years, we have successfully identified microglial 
proteins CD87 [54], RAGE, CD33 [55], TREM-2 [56], TLR-2, -3, -4 along with HLA-DR, IBA-1, 
CD68 in AD tissues.
Our experience with antibodies when using these tissues identified some features that help 
increase the chances of successful immunolocalization. One company—R & D Systems—
Biotechne, Minneapolis, MN—have produced many of their antibodies using a relatively 
unique strategy for the industry. Many of their antibodies were prepared from proteins of 
interest expressed in eukaryotic cells. These proteins will be glycosylated in a similar manner 
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to what might be expected in human tissues. In addition, the immunizing proteins usually 
cover the majority of the native protein, and thus preserve some of the secondary protein 
structure that affects antigenicity, along with containing multiple antigenic epitopes. These 
proteins produce antibodies with immunogenicity superior to the strategy of many compa-
nies that use short synthetic peptide sequences of 10–20 amino acids as immunogens, and then 
conjugated to a carrier prior to animal immunization. Our experience with R & D Systems 
affinity purified polyclonal antibodies has generally been favorable for use on lightly-fixed 
tissues. These antibodies will contain a range of epitopes that can increase the likelihood of 
identifying epitopes on proteins not severely affected by fixation. The use of large protein 
antigens to prepare polyclonal does have some drawbacks as there is the potential for cross 
reactivity with other related proteins. Quality control is dependent on being able to carry out 
protein absorption of antibody to show removal of tissue reactivity, along with western blot 
detection of specific protein bands.
Figure 2 (panels A and B) illustrates our experience using an R & D Systems antibody to 
Toll-like receptor (TLR)-3 (AF1487) to identify microglia in AD brains, and an R & D Systems 
polyclonal antibody to CD206 (AF2535), which failed to identify microglia (panels D and E). 
The TLR-3 polyclonal antibody could identify structures in human brain microglia (Figure 2, 
panels A and B). One comment is that if western blots are carried out using complex material 
such as brain material, the presence of other protein bands, besides the full length protein 
should be anticipated (Figure 2, panel C). Most functional proteins are either cleaved dur-
ing their normal function, for example loss of leader sequences, cleaved to produce secreted 
forms, or broken down as part of cellular metabolism. Interestingly, a monoclonal antibody 
to TLR-3 produced with the same immunizing protein could not stain microglia in tissue, 
but this antibody will be specific for only a single epitope present in the immunizing protein. 
We have had similar experience with an R &D systems antibody to CD206 (Figure 2, panels 
D and E), also known as macrophage mannose receptor, produced against a eukaryotic cell 
expressed protein. This protein has been defined as a prototypical marker for M2a alterna-
tive activation as its expression is induced in the presence of IL-4. We used this antibody to 
determine if there was evidence for alternative activation microglia in human brains. Using 
this antibody, which on western blots could detect specific bands on brain samples, did not 
identify microglia in any of the control or AD tissue sections we stained. Noticeable however 
was the strong CD206 staining of round cells (perivascular macrophages) located within 
or around the vessels present in the brain sections. This is similar to a published finding 
[34]. This seems to indicate alternative activated macrophages are common in vessels, while 
alternative activated microglia are not present in neuropil. In human brains, identifying 
expression of inflammatory associated molecules at the RNA or protein level using brain 
homogenates need to be interpreted with caution as significant numbers of blood cells can 
be trapped within the tissue [57]. Confirmation of findings by immunohistochemistry is 
needed when making observations relevant to microglia. The absence of alternative acti-
vated markers in AD brain samples was confirmed for the CD200 receptor (CD200R). This 
is a myeloid specific receptor that is activated by the ligand CD200 to induce anti-inflamma-
tory signaling. We showed that it was induced by IL-4 and IL-13 and fit the classical defini-
tion of an M2a marker, similar to CD206. Using several antibodies, including R&D Systems 
polyclonal antibody (AF3414) and a custom peptide antibody, we could not localize CD200R 
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immunoreactivity to brain microglia even though protein and mRNA expression of CD200R 
are detectable in human brains [58].
One marker that seems to have been overlooked in microglial profiling in tissue is CD14, 
the LPS co- receptor. This receptor is a classical M1-like activation marker with upregulation 
Figure 2. Approaches to microglial phenotyping in Alzheimer’s disease brains. (A) and (B) Immunohistochemistry for 
a new marker for microglia (toll-like receptor-3: TLR-3 in human brains. Double immunostaining for TLR-3 (purple) 
colocalizing with IBA-1 microglia in (A) non-demented control middle temporal gyrus and (B) Alzheimer’s disease 
case. See text for further explanation. These findings were obtained using R&D Systems antibody (AF1868). (C) Western 
blot of human brain samples for TLR-3. This panel illustrates that protein bands other than full length peptides can be 
present in biological samples. (D) and (E) Absence of alternatively activated microglia expressing CD206 in ND (D) or 
AD (E) temporal cortex brain sections but positive expression in perivascular/vascular macrophages. (F) and (G) The 
proinflammatory marker CD14 does show increased expression by microglia in AD cases (purple) colocalizing with 
IBA-1 immunoreactivity brain Strong positive staining is present in perivascular/vascular macrophages (purple) is also 
a feature.
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associated with proinflammatory activation. There has only been a single study describing 
microglial immunohistochemistry in human AD brains for CD14 [43]. Using short fixation 
tissue, we reexamined expression of this marker (Figure 2, panels F and G). It is strongly 
expressed by most vascular macrophages of all cases (Figure 2, panel F—ND case), but 
increased expression was readily detectable in subsets of IBA-1 microglia in AD cases (Figure 2, 
panel G—purple). As CD14 can bind Aβ with proinflammatory activation through interaction 
with TLR-2 or TLR-4, increased CD14 expression could be a more used marker for defining 
cytotoxic microglia.
4.3. Profiling TREM-2 microglia in human brains
This discussion is of particular relevance for considering microglial phenotyping of TREM-2 
positive microglia. Considerable interest in the role of TREM-2 in AD has spurred new inter-
est in neuroinflammation and AD. A single nucleotide polymorphism (SNP) in the TREM-2 
gene (rs75932628) that results in a mutation in the TREM-2 protein (R47H) can increase the risk 
of developing AD by 2- to 11-fold depending on the population studied [59, 60]. Mutations in 
TREM-2 or its adaptor protein DAP12 were first identified in Nasu-Hakola disease, which leads 
to early onset dementia amongst other symptoms [61]. The mutation appears to lead to loss of 
function of the TREM-2 protein, whose normal function is to promote phagocytosis of apoptotic 
neurons through binding to heat shock protein 70 (hsp70) or different conformations of lipids. 
There have been few studies of immunohistochemistry of TREM-2 in human AD brains, which 
appears mainly due to lack of robust antibodies for pathological work. We published one of 
the first studies that showed plaque- and tangle-associated microglia were positive for TREM-2 
[56]. In this study, we had to screen a number of antibodies for specificity and sensitivity in 
human brain tissue. The best results were obtained with an R&D Systems polyclonal antibody 
to TREM-2 (AF1828) prepared using a eukaryotic cell expressed protein corresponding to 75% 
of the protein and to the complete extracellular domain. A recent study of TREM-2 expression 
in AD frontal cortex using an antibody prepared using a peptide corresponding to N-terminal 
amino acids 29–59 of human TREM2 (ab175262, Abcam, Cambridge, MA) showed specific-
ity by western blots, but these authors presented no data on TREM2 immunohistochemistry 
[62]. TREM-2 expression is restricted to dendritic/myeloid cells and is high in brain microglia. 
Specificity of commercial antibodies has been an issue, but also the sensitivity of detection. Two 
studies have concluded that TREM-2 was not expressed by microglia in brain, but both studies 
employed FFPE tissue samples with antigen retrieval [63, 64]. One study showed that the R&D 
antibody was specific for TREM-2, similar to our published work, but they could not demon-
strate microglial TREM-2 immunoreactivity [63]. Similar to our previous studies, we employed 
lightly fixed brain tissues that were not paraffin-embedded [56]. With these sections, we could 
demonstrate specific TREM2 localization to microglia [56]. Our finding is reasonable as TREM-2 
has been localized to plaque-associated microglia in AD model transgenic mice [65].
5. Does expression of antigen correlate with identifiable function
How does antigen expression relate to demonstrated microglial function? With the exception 
of HLA-DR and IBA-1, most studies of microglia in human brains have not been adequately 
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replicated. Immunohistochemistry is not a quantitative technique due to the amplification 
technologies used along with the non-availability of standards for comparison, but the stud-
ies by Boche and colleagues using semi-quantitative measures deserve mention [10, 14, 66, 
67]. Using a large series of brain samples and the expression of different markers, including 
CD64, MSR-A, CD68, HLA-DR and IBA-1, it was shown that microglia could be subtyped 
depending on their profile. These studies set the standards for microglial profiling in human 
brains. These studies employed two measures for analysis; the area of immunoreactivity and 
the numbers of positive cells. These studies attempted to assign phagocytic function or activa-
tion function to the microglia in relation to the type of pathology. One interesting observation 
was the lack of significant correlation between expression levels of these different antigens 
by microglia. These markers are related to different functions, with CD64, MSR-1, and C68 
being related to phagocytosis, HLA-DR with antigen presentation and IBA-1 with microglial 
motility. Studies of TREM-2 and CD33 in AD brains demonstrated upregulated expression 
in AD brains, but both receptors induce inhibitory signaling when activated [55, 56]. There 
is evidence that upregulation of such activated microglial proteins encountered in disease 
tissue could be to have an inhibitory effect on inflammation, not amplifying inflammatory 
responses.
5.1. Where are the non-activated microglia in AD or aging brains?
In recent years, gene discovery methodology (RNA sequencing, microarrays, single cell 
sorting) has been applied to studies of microglia. One particularly interesting marker iden-
tified is the purinergic ADP/ATP receptor P2RY12. This was shown to be highly expressed 
by microglia (human and rodent) compared to macrophages. In addition, it appears to be 
a marker of non-activated microglia as expression becomes rapidly downregulated upon 
inflammatory activation with LPS [68]. P2RY12 has been defined as a M2 marker as it is 
unregulated in vitro in human microglia by treatment with IL-4 [69]. A common concept 
over the years about neuroinflammation and AD is that widespread proinflammatory acti-
vation is a significant and extensive feature. The expression that the brain is on fire has 
been used more than once in review articles of AD inflammation. If inflammation is wide-
spread in pathological affected tissues, one would expect that P2RY12 expression would 
be very low or absent in AD brains. Our preliminary findings show that this is not the situ-
ation; there were many P2RY12 microglia in regions with severe AD pathology. Although 
western blot and mRNA studies showed no difference in expression of this gene between 
AD and control samples, however by immunohistochemistry, there was a very specific 
distribution of P2RY12 positive and negative microglia in brains in relation to pathological 
structures.
6. Future directions
The potential benefits for complete definition of microglial phenotypes by immunohisto-
chemistry in human brains could be significant. The development of effective inflammation-
focused therapies for AD requires the identification of therapeutic targets that are relevant 
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to the human disease, not to models of disease in a transgenic animal or cell culture. AD is 
a uniquely human disease of the elderly, with pathology having developed for years before 
dementia becomes observable. In transgenic models, disease pathology can develop over 
weeks. There have been many agents that can reverse plaque development and inflamma-
tion in AD mice models that have failed to be effective in humans. There are many challenges 
involved in human focused studies, but the benefits of having human disease targets vali-
dated in human tissue could involve significant saving in time and resources from pursuing 
the wrong approaches. Immunohistochemistry is not considered a state of art technique in the 
twenty-first century as the technologies have not much changed in 30 years, but ultimately 
it is required to show that gene discovery findings are valid. The need for large numbers of 
high quality human tissue samples has been one limitation, but this can be addressed by 
collaborative studies. Brain tissue that has been consistently prepared with appropriate clini-
cal and pathological records allow studies involving progressive changes in pathology from 
negligible to severe rather than the less useful classification of control or AD. There is also 
a need for improved expectations on the performance of antibodies. The performance and 
reproducibility of antibodies in all biological experiments has been a growing concern [70], 
but ultimately it is the responsibility of the experimenter/pathologist to determine the suit-
ability of antibodies used to make a unique observation. The field of neuroinflammation in 
AD has been reinvigorated with discoveries about TREM-2 having a direct link to AD risk. To 
be able to reliably identify TREM-2 positive microglia in brain is needed to fully understand 
its role in sporadic AD, and validate the large numbers of model studies that have proposed 
therapeutic strategies for AD focused on TREM-2.
7. Conclusions
Microglia represent approximately 10% of the total cell population in human brain, but it is 
now appreciated how complex their responses are to pathological stimuli and for maintain-
ing healthy neurons. Treating pathological inflammation in AD with broad spectrum agents 
(e.g., cyclooxygenase inhibitors) may do more harm than good. If the microglial responses to 
pathology are highly dependent on the microenvironment; for example one microglia may 
be producing excess TNF-α while an adjacent one is attempting to remove the pathological 
stimuli, then treatments need to be targeted appropriately. This will only be possible if the 
microglia actively involved in AD can be adequately profiled.
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